🧾 What This Document Is

This is an 8-K filing, which companies use to announce major events to investors. It includes two key exhibits:

The full employment contract for Zymeworks' new CFO, Kristin Stafford.
A press release officially announcing her appointment. 👉 In simple terms, the company is telling the public, "Here's our new financial boss, and here are the exact details of her job offer."

🏢 What Zymeworks Does

👉 In simple terms, Zymeworks is a biotech company with a two-part business:

Asset Manager: It owns rights to promising drugs developed by others (like Ziihera®) and earns money through royalties and partnerships.
Drug Developer: It's also actively creating its own new, complex biotherapeutic drugs (like pasritamig) to treat tough diseases like cancer. They use their own technology platforms to design these next-gen medicines, often partnering with bigger companies to bring them to market.

👥 Meet the New CFO: Kristin Stafford

The hiring of a CFO is a major event. Here’s who they brought on board:

Experience: Comes from Royalty Pharma, where she was Senior VP and Chief Accounting Officer. Her background is heavy in finance, capital markets, and strategic deals within the life sciences industry.
Other Roles: Serves on the board of Novocure and has past experience at Ernst & Young and Deloitte.
Education: CPA with a B.Sc. in Business Administration from Sonoma State University. 👉 This hire signals that Zymeworks is prioritizing financial strategy and deal-making as it grows its pipeline.

💰 The CFO's Compensation Package

The employment contract spells out exactly what Kristin Stafford will be paid. This is what it takes to attract top financial talent in biotech:

Base Salary: $520,000 USD per year.
Signing Bonus: $52,000 USD (must be repaid if she leaves within the first year).
Annual Bonus Target: 45% of her base salary (so up to ~$234,000), based on company performance.
Equity (The Big Incentive):
- Stock Options: To buy 178,000 shares of Zymeworks stock.
- Restricted Stock Units (RSUs): 119,000 shares + a special grant of 50,000 more shares.
- These vest over 3-4 years, meaning she earns them gradually by staying with the company. 👉 The total package is designed to align her long-term success with the company's stock performance.

🚀 Key Terms of the Employment Deal

Beyond pay, the contract outlines important rules and protections:

"At-Will" Employment: Either side can end the job at any time, for any reason.
Severance: If fired without cause, she's entitled to:
- 12 months of base salary (for the first 3 years).
- This increases by 1 month per year after that, up to 18 months total.
- Full acceleration of all unvested equity if this happens within 12 months after a "Change of Control" (like the company being sold).
Protecting Company Secrets: She must keep all confidential information (like research and business plans) private and cannot work for a competitor.
Dispute Resolution: Any legal disputes must go through binding arbitration, not public court.

📦 What This Signals for Zymeworks

This hiring move reveals the company's current strategic priorities:

👍 Financial Discipline: Bringing in a CFO from a royalty-focused firm suggests a focus on managing cash flow from their licensed assets and making smart capital allocation decisions.
👍 Experience for Growth: Her background in complex transactions is valuable as Zymeworks advances its pipeline and seeks strategic partnerships.
⚠️ Key-Person Risk: As with any executive hire, the company's success becomes partly tied to this individual's performance and retention.

🔮 What's Next

With a new CFO in place, watch for:

Strategic Updates: Look for future announcements on financial strategy, potential partnerships, or capital raising.
Pipeline Progress: Her role will be crucial in funding and managing the economics of drug development.
Investor Confidence: The market will judge the hire based on Zymeworks' subsequent financial performance and strategic execution.

🧠 The Analogy

Hiring Kristin Stafford is like a sports team hiring a star General Manager. The team (Zymeworks) has promising players (its drug pipeline) and valuable stadium rights (its licensed assets). The new GM (Stafford) is brought in with a big contract not to play, but to expertly manage the salary cap (capital), negotiate complex trades (partnerships), and build a championship-caliber roster for the long term. Her past success with a different team's assets (Royalty Pharma) is why she was hired.

📇 Key Contacts & People

New Executive:

Kristin Stafford, Executive Vice President, Chief Financial Officer (Employee)

Company Representatives (from signing):

Kenneth Galbraith, Chair and Chief Executive Officer (for Zymeworks Biopharmaceuticals Inc.)

Investor & Media Inquiries:

Shrinal Inamdar, Vice President, Investor Relations | (604) 678-1388 | [email protected]
Diana Papove, Vice President, Corporate Communications | (604) 678-1388 | [email protected]

🧩 Final Takeaway

Zymeworks is strategically bolstering its leadership team by hiring an experienced finance chief from the royalty and capital markets space. This move underscores a focus on disciplined financial management and strategic deals as the company advances its drug pipeline and manages its portfolio of healthcare assets.

Zymeworks Inc. — 8-K Filing